Nobel prize winning CRISPR technology to be applied in development of genetically engineered animal models

DUBLIN & SHIZUOKA, Japan--(BUSINESS WIRE)--ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Japan SLC, Inc., a biotechnology company providing animal models to the research community, today announced a non-exclusive license agreement granting Japan SLC access to ERS Genomics� CRISPR/Cas9 patent portfolio.

Japan SLC supports research organizations by providing animal models from its varied portfolio, including outbred, inbred, immunodeficient, congenic, hybrid, disease models and transgenic. The addition of CRISPR/Cas9 technology to the company�s toolbox will enable the expansion of its offering.

ERS Genomics holds an exclusive worldwide license from co-founder and recent Nobel prize winner Dr. Emmanuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform.

�We are proud to add Japan SLC to our growing list of partners in Japan applying CRISPR/Cas9 technology to its service offerings,� said Eric Rhodes, CEO of ERS Genomics. �Japan SLC�s animal production and supply are of high quality, and we are very pleased that it has chosen to license CRISPR/Cas9 technology through ERS Genomics.�

�Our production and supply of laboratory animals will benefit greatly through the use of the revolutionary CRISPR/Cas9 technology,� commented Hirotaka Takagi, President, Japan SLC. �We are very excited to sign this licensing agreement with ERS Genomics which will enable us to produce CRISPR-edited mouse and rat models.�

Financial details of the agreement are not disclosed.

Contacts

Katie Odgaard

Zyme Communications

Tel: +44(0)7787 502 947

Email: [email protected]